Puma Biotechnology Inc (PBYI): Price and Financial Metrics
PBYI Price/Volume Stats
Current price | $5.30 | 52-week high | $7.73 |
Prev. close | $5.58 | 52-week low | $2.13 |
Day low | $5.24 | Volume | 275,380 |
Day high | $5.60 | Avg. volume | 626,848 |
50-day MA | $5.53 | Dividend yield | N/A |
200-day MA | $3.99 | Market Cap | 255.50M |
PBYI Stock Price Chart Interactive Chart >
PBYI POWR Grades
- PBYI scores best on the Value dimension, with a Value rank ahead of 99.55% of US stocks.
- PBYI's strongest trending metric is Quality; it's been moving up over the last 26 weeks.
- PBYI's current lowest rank is in the Momentum metric (where it is better than 10.87% of US stocks).
PBYI Stock Summary
- PUMA BIOTECHNOLOGY INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 92.63% of US listed stocks.
- PBYI's current price/earnings ratio is 56.18, which is higher than 87.68% of US stocks with positive earnings.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 7.05 for PUMA BIOTECHNOLOGY INC; that's greater than it is for 83.84% of US stocks.
- If you're looking for stocks that are quantitatively similar to PUMA BIOTECHNOLOGY INC, a group of peers worth examining would be ATEN, CSGS, VMEO, ALKS, and ALSN.
- PBYI's SEC filings can be seen here. And to visit PUMA BIOTECHNOLOGY INC's official web site, go to www.pumabiotechnology.com.
PBYI Valuation Summary
- In comparison to the median Healthcare stock, PBYI's price/sales ratio is 78.57% lower, now standing at 0.9.
- Over the past 142 months, PBYI's EV/EBIT ratio has gone up 35.4.
Below are key valuation metrics over time for PBYI.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
PBYI | 2023-12-29 | 0.9 | 5.3 | 55.4 | 13.3 |
PBYI | 2023-12-28 | 0.9 | 5.3 | 55.7 | 13.3 |
PBYI | 2023-12-27 | 0.9 | 5.3 | 55.6 | 13.3 |
PBYI | 2023-12-26 | 0.9 | 5.5 | 57.1 | 13.6 |
PBYI | 2023-12-22 | 0.9 | 5.1 | 52.7 | 12.7 |
PBYI | 2023-12-21 | 0.8 | 4.8 | 50.4 | 12.2 |
PBYI Growth Metrics
- The 4 year cash and equivalents growth rate now stands at -15.69%.
- Its 3 year cash and equivalents growth rate is now at 20.35%.
- Its 2 year cash and equivalents growth rate is now at -30.71%.
The table below shows PBYI's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 217.713 | -28.945 | 9.832 |
2022-06-30 | 206.856 | -35.706 | -34.48 |
2022-03-31 | 200.722 | -21.906 | -48.957 |
2021-12-31 | 253.155 | 20.65 | -29.126 |
2021-09-30 | 250.355 | 20.45 | -48.244 |
2021-06-30 | 254.864 | 11.672 | -35.035 |
PBYI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PBYI has a Quality Grade of C, ranking ahead of 66.91% of graded US stocks.
- PBYI's asset turnover comes in at 1.012 -- ranking 23rd of 682 Pharmaceutical Products stocks.
- ACAD, TVTX, and CTMX are the stocks whose asset turnover ratios are most correlated with PBYI.
The table below shows PBYI's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 1.012 | 0.749 | -0.448 |
2021-06-30 | 0.995 | 0.755 | -0.266 |
2021-03-31 | 1.058 | 0.780 | -0.137 |
2020-12-31 | 0.905 | 0.825 | -0.449 |
2020-09-30 | 0.955 | 0.836 | -0.355 |
2020-06-30 | 1.008 | 0.842 | -0.212 |
PBYI Price Target
For more insight on analysts targets of PBYI, see our PBYI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $8.63 | Average Broker Recommendation | 2.06 (Hold) |
Puma Biotechnology Inc (PBYI) Company Bio
Puma Biotechnology is a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. The company was founded in 2010 and is based in Los Angeles, California.
Latest PBYI News From Around the Web
Below are the latest news stories about PUMA BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate PBYI as an investment opportunity.
Iovance (IOVA) Falls After Clinical Update on Lung Cancer DrugIovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines. |
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca OnbodyThe FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news. |
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer CandidateThe FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises. |
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive CandidiasisCidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%. |
Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer ProgramSanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint. |
PBYI Price Returns
1-mo | -17.96% |
3-mo | 22.40% |
6-mo | 101.52% |
1-year | 107.84% |
3-year | -44.44% |
5-year | -86.34% |
YTD | 22.40% |
2023 | 2.36% |
2022 | 39.14% |
2021 | -70.37% |
2020 | 17.26% |
2019 | -57.00% |
Continue Researching PBYI
Want to do more research on Puma Biotechnology Inc's stock and its price? Try the links below:Puma Biotechnology Inc (PBYI) Stock Price | Nasdaq
Puma Biotechnology Inc (PBYI) Stock Quote, History and News - Yahoo Finance
Puma Biotechnology Inc (PBYI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...